Schrodinger, Inc.
SDGR Nasdaq Pharmaceutical Preparations Financials FY2019โFY2025
Last close ยท Oct 23, 2026
$23.80
5.3%What Schrodinger, Inc. does
No business description yet.
- Legal name
- Schrodinger, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Feb 25, 2026
- Accession ยท CIK
- 0001490978-26-000010
0001490978
Revenue and margins
Schrodinger, Inc. had $256M of revenue in fiscal 2025, up 23.3% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $12.5M in fiscal 2025, 4.9% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Schrodinger, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 1.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably Schrodinger, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $576M | $451M | $463M | $352M | $395M |
| Current ratio | 6.9x | 4.9x | 4.2x | 3.3x | 2.7x |
| Quick ratio | 6.9x | 4.9x | 4.2x | 3.3x | 2.7x |
| Total assets | $756M | $689M | $803M | $823M | $726M |
| Total liabilities | $199M | $241M | $254M | $402M | $362M |
| Shareholders' equity | $557M | $448M | $549M | $421M | $364M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | 5 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 2 / 8 | 4 / 8 |
| Accruals ratio | 1.0% | โ9.1% | โ4.0% | โ4.1% | 23.8% | โ3.7% | โ15.1% |
| Altman Z'' | โ2.50 | 9.61 | 5.58 | 2.78 | 2.95 | 0.84 | โ0.33 |
7 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $85.5M | $108M | $138M | $181M | $217M | $208M | $256M |
| Gross profit | $49.1M | $63.5M | $65.6M | $101M | $141M | $132M | $143M |
| Research and development | $39.4M | $64.7M | $90.9M | $126M | $182M | $202M | $173M |
| Operating income | โ$38.7M | โ$60.9M | โ$111M | โ$147M | โ$177M | โ$209M | โ$167M |
| Pretax income | โ$26.0M | โ$26.3M | โ$101M | โ$149M | $42.9M | โ$186M | โ$102M |
| Income tax | โ$0.3M | $0.3M | $0.4M | $0.1M | $2.2M | $1.4M | $0.9M |
| Net income | โ$24.6M | โ$24.5M | โ$100M | โ$149M | $40.7M | โ$187M | โ$103M |
| Diluted EPS | โ$4.09 | โ$0.41 | โ$1.42 | โ$2.10 | $0.54 | โ$2.57 | โ$1.41 |
| Diluted shares | 0.01B | 0.06B | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B |
| Cash flow | |||||||
| Cash from operations | โ$26.1M | $16.8M | โ$70.7M | โ$120M | โ$137M | โ$157M | $13.9M |
| Capital expenditure | $1.8M | $2.5M | $7.2M | $8.0M | $13.4M | $7.3M | $1.4M |
| Free cash flow | โ$27.9M | $14.2M | โ$77.8M | โ$128M | โ$150M | โ$165M | $12.5M |
| Depreciation and amortization | $3.6M | $3.7M | $2.8M | $4.3M | $5.6M | $6.2M | $6.0M |
| Stock-based compensation | $2.2M | $10.5M | $26.5M | $39.6M | $47.8M | $49.9M | $43.0M |
| Acquisitions | โ | $0.0M | $0.0M | $6.4M | $0.0M | $0.0M | โ |
| Balance sheet | |||||||
| Cash and short-term investments | $85.8M | $643M | $576M | $451M | $463M | $352M | $395M |
| Current assets | $119M | $683M | $625M | $534M | $568M | $635M | $519M |
| Current liabilities | $45.0M | $73.2M | $91.2M | $109M | $134M | $192M | $189M |
| Property and equipment, net | $6.3M | $5.1M | $10.0M | $14.2M | โ | โ | โ |
| Goodwill | โ | โ | $0.0M | $4.8M | $4.8M | $4.8M | $4.8M |
| Intangible assets | โ | โ | $0.0M | $0.6M | $0.0M | โ | โ |
| Total assets | $155M | $746M | $756M | $689M | $803M | $823M | $726M |
| Total liabilities | $57.0M | $122M | $199M | $241M | $254M | $402M | $362M |
| Preferred stock | โ | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | โ$93.4M | $624M | $557M | $448M | $549M | $421M | $364M |
| Margins | |||||||
| Gross margin | 57.4% | 58.7% | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| Operating margin | โ45.3% | โ56.4% | โ80.8% | โ81.1% | โ81.9% | โ100.8% | โ65.2% |
| EBITDA margin | โ41.0% | โ53.0% | โ78.7% | โ78.7% | โ79.3% | โ97.9% | โ62.9% |
| Net margin | โ28.7% | โ22.6% | โ72.8% | โ82.4% | 18.8% | โ90.2% | โ40.4% |
| FCF margin | โ32.6% | 13.2% | โ56.4% | โ70.6% | โ69.3% | โ79.3% | 4.9% |
| Returns | |||||||
| Return on capital employed | โ35.1% | โ9.1% | โ16.8% | โ25.3% | โ26.5% | โ33.1% | โ31.1% |
| Return on equity | โ | โ9.2% | โ17.0% | โ29.7% | 8.2% | โ38.6% | โ26.3% |
| Return on assets | โ15.8% | โ5.4% | โ13.4% | โ20.6% | 5.5% | โ23.0% | โ13.3% |
| Return on tangible equity | โ | โ3.9% | โ18.0% | โ33.7% | 7.5% | โ44.9% | โ28.7% |
| Growth | |||||||
| Revenue growth | โ | 26.4% | 27.6% | 31.2% | 19.7% | โ4.2% | 23.3% |
| Net income growth | โ | โ | โ | โ | โ | โ559.5% | โ |
| EPS growth | โ | โ | โ | โ | โ | โ575.9% | โ |
| FCF growth | โ | โ | โ647.4% | โ | โ | โ | โ |
| Share count change | โ | 899.7% | 17.6% | 0.8% | 5.4% | โ3.1% | 1.1% |
| Financial health | |||||||
| Current ratio | 2.6x | 9.3x | 6.9x | 4.9x | 4.2x | 3.3x | 2.7x |
| Quick ratio | 2.6x | 9.3x | 6.9x | 4.9x | 4.2x | 3.3x | 2.7x |
| Capital allocation | |||||||
| Capex / revenue | 2.1% | 2.3% | 5.2% | 4.4% | 6.2% | 3.5% | 0.6% |
| Stock comp / revenue | 2.6% | 9.8% | 19.2% | 21.9% | 22.1% | 24.0% | 16.8% |
| Quality scores | |||||||
| Piotroski F-score | โ | 5.0 | 2.0 | 3.0 | 4.0 | 2.0 | 4.0 |
| Altman Z'' | โ2.5 | 9.6 | 5.6 | 2.8 | 3.0 | 0.8 | โ0.3 |
| Accruals ratio | 1.0% | โ9.1% | โ4.0% | โ4.1% | 23.8% | โ3.7% | โ15.1% |
Source: SEC EDGAR XBRL filings (CIK 0001490978). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
